Release brakes: chimeric antigen receptor T cells with PD-1 switch receptor

被引：1
|
作者：
Chmielewski, Markus [1 ,2 ]
Abken, Hinrich [1 ,2 ]
机构：
[1] Univ Cologne, Ctr Mol Med Cologne, Robert Koch Str 21, D-50931 Cologne, Germany
[2] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
来源：
TRANSLATIONAL CANCER RESEARCH | 2016年 / 5卷 / 03期
关键词：
IMMUNE CHECKPOINTS; SOLID TUMORS; IMMUNOTHERAPY; RESISTANCE; BLOCKADE; EFFICACY; EXPRESS; CANCER;
D O I：
10.21037/tcr.2016.06.25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：229 / 232
页数：4
相关论文
共 50 条
  • [1] Engineering Chimeric Antigen Receptor T Cells against Immune Checkpoint Inhibitors PD-1/PD-L1 for Treating Pancreatic Cancer
    Yang, Ching-Yao
    Fan, Ming Huei
    Miao, Carol H.
    Liao, Yi Jen
    Yuan, Ray-Hwang
    Liu, Chao Lien
    MOLECULAR THERAPY ONCOLYTICS, 2020, 17 : 571 - 585
  • [2] Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma
    Guo, Xingliang
    Jiang, Hua
    Shi, Bizhi
    Zhou, Min
    Zhang, Honghong
    Shi, Zhimin
    Du, Guoxiu
    Luo, Hong
    Wu, Xiuqi
    Wang, Yi
    Sun, Ruixin
    Li, Zonghai
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [3] PD-1 silencing impairs the anti-tumor function of chimeric antigen receptor modified T cells by inhibiting proliferation activity
    Wei, Jianshu
    Luo, Can
    Wang, Yao
    Guo, Yelei
    Dai, Hanren
    Tong, Chuan
    Ti, Dongdong
    Wu, Zhiqiang
    Han, Weidong
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [4] Chimeric antigen receptor T cells
    Bories, Pierre
    Ysebaert, Loic
    BULLETIN DU CANCER, 2021, 108 (10) : S55 - S64
  • [5] A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells**
    Cao, Wenyue
    Geng, Zhi Zachary
    Wang, Na
    Pan, Quan
    Guo, Shaodong
    Xu, Shiqing
    Zhou, Jianfeng
    Liu, Wenshe Ray
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2022, 61 (10)
  • [6] Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain
    Zhang, Ang
    Wang, Shenyu
    Sun, Yao
    Zhang, Yikun
    Zhao, Long
    Yang, Yang
    Zhang, Yijian
    Xu, Lei
    Lei, Yangyang
    Du, Jie
    Chen, Hu
    Duan, Lian
    He, Mingyi
    Shi, Lintao
    Liu, Lei
    Wang, Quanjun
    Hu, Liangding
    Zhang, Bin
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2023, 12 (01)
  • [7] Sulforaphane enhances the antitumor response of chimeric antigen receptor T cells by regulating PD-1/PD-L1 pathway
    Shen, Chunyi
    Zhang, Zhen
    Tian, Yonggui
    Li, Feng
    Zhou, Lingxiao
    Jiang, Wenyi
    Yang, Li
    Zhang, Bin
    Wang, Liping
    Zhang, Yi
    BMC MEDICINE, 2021, 19 (01)
  • [8] Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth
    Qin, Le
    Zhao, Ruocong
    Chen, Dongmei
    Wei, Xinru
    Wu, Qiting
    Long, Youguo
    Jiang, Zhiwu
    Li, Yangqiu
    Wu, Haipeng
    Zhang, Xuchao
    Wu, Yilong
    Cui, Shuzhong
    Wei, Wei
    Yao, Huihui
    Liu, Zixia
    Cao, Su
    Yao, Yao
    Zhang, Zhenfeng
    Li, Peng
    BIOMARKER RESEARCH, 2020, 8 (01)
  • [9] Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells
    Robbins, Yvette
    Greene, Sarah
    Friedman, Jay
    Clavijo, Paul E.
    Van Waes, Carter
    Fabian, Kellsye P.
    Padget, Michelle R.
    Sater, Houssein Abdul
    Lee, John H.
    Soon-Shiong, Patrick
    Gulley, James
    Schlom, Jeffrey
    Hodge, James W.
    Allen, Clint T.
    ELIFE, 2020, 9 : 1 - 18
  • [10] Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells
    Supimon, Kamonlapat
    Sangsuwannukul, Thanich
    Sujjitjoon, Jatuporn
    Chieochansin, Thaweesak
    Junking, Mutita
    Yenchitsomanus, Pa-thai
    CYTOTHERAPY, 2023, 25 (02) : 148 - 161
12345